Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meiji Seika Readies Oral Version of Carbapenem Antibiotic (Japan)

This article was originally published in PharmAsia News

Executive Summary

Meiji Seika Kaisha Ltd. is moving forward with the last stage of clinical tests on ME1211, an oral form of a carbapenem antibiotic. The firm plans to apply for production and marketing approval as soon as this year. Meiji Seika acquired sole development, production, and marketing rights to the antibiotic for Japan and 15 Asian firms five years ago from Wyeth KK's predecessor. Carbapenem antibiotics work well against bacteria that have proven resistant to other medications, including penicillin and methicillin. So far, though, they have just been available as injections. ME1211 is alleged to be the initial oral formula of a carbapenem antibiotic in the world. The firm hopes to eventually yield 10 billion yen ($86.1 million) annually in sales from ME1211. (Print Edition Only: Link to Full Text Unavailable
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel